atai Wins $11.4M NIDA Grant to Develop Non-Hallucinogenic Psychedelics for OUD • Australia’s Largest Private Health Insurer Funds Psilocybin for Treatment-Resistant Depression Pilot • Osmind and Bendable Share Real-World Outcomes from 88 Psilocybin Clients • Psychedelic Pipeline Bullseye Chart Update Log • Pennsylvania Lawmakers Talk Psychedelics in Hearing on Treatment-Resistant Depression • Reunion Upsizes Series A to $133M Following Phase 2 Success • Virtual Ketamine Startup ...| Psychedelic Alpha
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here, we speak to researchers about the trial, diving deeper into topics including the dose-response effect, the candidate’s safety profile, and non-pharmacological elements of the study, including the company’s decision not to record any of the sessions in its Phase 2b or Phase 3 studies.| Psychedelic Alpha
This morning, the UK's Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related guidance it published for psychiatrists working on studies of psychedelics.| Psychedelic Alpha
From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer research hospital Gustave Roussy, Dr. Florence Butlen-Ducuing has had a front-row seat to the evolution of psychedelic research and drug development in Europe.| Psychedelic Alpha
Explore our interactive database of psychedelic patent activity in August 2025 via our Pα+ interface.| Psychedelic Alpha
Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the three dealbreaking issues, speak with insiders and observers about its contents, and discuss what it might mean for Lykos’ road to resubmission.| Psychedelic Alpha
Psychedelic CEOs’ FDA Wish-List • APA Division 56 President Jessica Punzo on Psychologists and Psychedelics • Compass’ Phase 2 PTSD Study Published • Cybin Ousts CEO Doug Drysdale • DoD to Test Military for Psilocybin • MindMed's Phase 2b LSD for GAD Study Publishes • and more..| Psychedelic Alpha
The FDA is pushing researchers to reduce their use of animal models and instead adopt ‘new approach methodologies’, like organoids and AI modelling. Here, Dr. Alaina Jaster speaks with psychedelic scientists and drug developers to unpack the debate.| Psychedelic Alpha
One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth…| Psychedelic Alpha
Here, we share Dr. Alaina Jaster’s observations from the inaugural Neurobiology of Psychedelics Gordon Research Conference, where leading scientists gathered to explore various realms of psychedelic…| Psychedelic Alpha
